Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M3:0d2Z2dmO2aX;uJGF{e2G7 Mnr3NE4yNTNyIN88US=> NELMRpk1QCCq NEWyPZFqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? NXm1Z45pOjZ3MUOxO|I>
H460 M17jZ2Z2dmO2aX;uJGF{e2G7 Mki2NE4yNTNyIN88US=> MoXoOFghcA>? M2qzSolv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt MWWyOlUyOzF5Mh?=
HKESC-2 NIDjTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTNlDDqM7:TR?= NYT2V2RMPDkEoHlCpC=> NHqxU|B{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? MonSNlY1PzR4OUO=
CaES-17 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT4bG4zOMLizszN NIPvWWg1QMLiaNMg Mm\0d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh MUSyOlQ4PDZ7Mx?=
HKESC-2 NGfL[I9CeG:ydH;zbZMhSXO|YYm= M2HmTlIxyqEQvF2= M3r2[VQ5yqCqwrC= MXny[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz MnTuNlY1PzR4OUO=
CaES-17 NYnjNZhRSXCxcITvd4l{KEG|c3H5 M4PYcVIxyqEQvF2= M3LacFQ5yqCqwrC= MoXkdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NInDUmUzPjR5NE[5Ny=>
A549 M3L2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PvOlUuOTZyIN88US=> MWi0POKhcMLi NFLTN|lFVVOR MUXJR|UxRTF4Mz60JO69VQ>? MYWyOlQ3PDZ2Mx?=
HCC827 NFjLVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1OU0yPjBizszN Mn\6OFjDqGkEoB?= M2XXXmROW09? M1u3S2lEPTB;NkmuNkDPxE1? NXm4dVhNOjZ2NkS2OFM>
A549 MXTBdI9xfG:|aYOgRZN{[Xl? MVS4NEDDvU1? MVi0POKhcMLi NEeze4RFVVOR NIXVZZhqdmS3Y3XzJIFxd3C2b4Ppdy=> NGLON4YzPjR4NE[0Ny=>
HCC827 M1nlbWFxd3C2b4Ppd{BCe3OjeR?= NITqfXU5OCEEtV2= M4foXFQ5yqCqwrC= MYLEUXNQ MYPpcoR2[2W|IHHwc5B1d3Orcx?= MXWyOlQ3PDZ2Mx?=
SGC-7901/DDP MmTjSpVv[3Srb36gRZN{[Xl? M3jVSFExyqEEtV2= NGDlTZAzPCCq M2HTeolvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MoXhNlY1ODd4NUO=
SGC-7901  NUXQfIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLoNlTDqGkEoB?= NIr6OFZKSzVyPUGxOU4xQCEQvF2= M3nqUVI3PDB5NkWz
SGC-7901/DDP NWn5UXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnoR3EzPMLiaNMg M1Ha[2lEPTB;M{WuOFUh|ryP MoK2NlY1ODd4NUO=
SGC-7901/DDP NVzUe4dESXCxcITvd4l{KEG|c3H5 NIHqfXEyOMLiwsXN NEjaV5EzPCCq Mo\0bY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> MkC3NlY1ODd4NUO=
SGC-7901/DDP NYfkPYF3TnWwY4Tpc44hSXO|YYm= NVjaUW9YOTEEoNM1US=> NF\hV2QzPCCq NGTwbVBqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= NH;6UGwzPjRyN{[1Ny=>
SGC-7901/DDP NVH1NFNoTnWwY4Tpc44hSXO|YYm= Mlv5NVDDqML3TR?= NIPyVYQzPCCq NFS1NWNk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> M{XmSVI3PDB5NkWz
H357 NW[4WGxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmG5O{42NzFyIN88US=> M1S3RlQ5KGh? MnTTSG1UVw>? M3T0PYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> MVmyOlAxQTh5NB?=
TAF NYHQWZhYTnWwY4Tpc44hSXO|YYm= Mo\nNVDDqML3TR?= MkLCO{Bl NIPRN5hi\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= MWeyOVk5PzF{Nx?=
TAF NH3NOGpHfW6ldHnvckBCe3OjeR?= M33MOFExyqEEtV2= MV[zNE0yOjBibXnu NEW2SYtxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> NV3JPZRvOjV7OEexNlc>
TAF NFHDNnZHfW6ldHnvckBCe3OjeR?= M3ntN|ExyqEEtV2= Mo\pOFghcA>? MlvMbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NUXJNYpyOjV7OEexNlc>
PANC-1 M{C5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3WdHgzOC94MD:xNFAh|ryP NELxNFMzPC92OD:3NkBp NUnHR4ZwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M33GZlI2QTd|ME[y
PANC-1 NYfiXmd2TnWwY4Tpc44hSXO|YYm= NHzqZWIzOC94MD:xNFAh|ryP NHPWdXozPCCq NEG1UY1ifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXTUZnROOjV7N{OwOlI>
HeLa  MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{naPVIxyqEQvF5CpC=> NVLwe3ZnOjUEoHi= MYnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MXqyOVc4ODR{Mx?=
SACC-83 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPvRoszOMLizszNxsA> NHfjSZUzPMLiaB?= MoDV[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MXmyOVc4ODR{Mx?=
HeLa  NFy2fGpCeG:ydH;zbZMhSXO|YYm= MV6yNOKh|ryPwrC= NE\jOHgzPMLiaB?= M3:5VIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NITyRYczPTd5MESyNy=>
SACC-83 MXnBdI9xfG:|aYOgRZN{[Xl? MVyyNOKh|ryPwrC= MViyOOKhcA>? MX;lcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz M1XoRVI2PzdyNEKz
HeLa  MnjPSpVv[3Srb36gRZN{[Xl? NXnadJo3OjBxNECvPFAh|ryP M4jJUFI1yqCq Mn;neZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M{juXlI2PzdyNEKz
SACC-83 NFzIbmZHfW6ldHnvckBCe3OjeR?= NW\adlM1OjBxNECvPFAh|ryP MWKyOOKhcA>? MkTxeZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M3[4T|I2PzdyNEKz
HLCZ01 NH\FbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHBNQKBmzZywrFCuW0> NX3WeZdLPDhiaB?= MWLEUXNQ Mn;ibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHXo[VczPTd{NEi5PS=>
HLCZ01 NF\RfFhHfW6ldHnvckBCe3OjeR?= NEe5e|M1OMLizszN MW[yOEBp M4\ZcmROW09? NYnTR2JpcW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MljiNlU4OjR6OUm=
HLCZ01 MVfBdI9xfG:|aYOgRZN{[Xl? NFnydHY1OMLizszN NHTkN2QzPCCq MYXEUXNQ NVTZVXc4\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z M3n3fFI2PzJ2OEm5
HLCZ01 NYPMOphLTnWwY4Tpc44hSXO|YYm= M4POSlQxyqEQvF2= MUGyOEBp MojISG1UVw>? M4OyRolv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> M4Wwd|I2PzJ2OEm5
MGC803 NUL1T|FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HjTVAuPjBizszN NHHOVIs4OiCq MXHJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= NX\5dYpyOjV5MEGzO|g>
SGC7901 NEDPWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMVYxKM7:TR?= NXLKdHhFPzJiaB?= MnHFTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= M4rQPVI2PzBzM{e4
MGC803 MofXSpVv[3Srb36gRZN{[Xl? MnX3OFDDqM7:TR?= NGDKRmo5NzF4L{K0JIg> MWL1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= NXHhW5hLOjV5MEGzO|g>
SGC7901 M17Hd2Z2dmO2aX;uJGF{e2G7 MUG0NOKh|ryP M3L2U|gwOTZxMkSgbC=> NWHvZlZpfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NWDnXXNEOjV5MEGzO|g>
MCF-7  Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XTbFEwOTBizszN M1HOdlczKGh? MnLySG1UVw>? MkPW[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NUm3UVJ{OjV4Nke1NVA>
MDA-MB-231  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XDfFEwOTBizszN NYXWenZtPzJiaB?= MnXrSG1UVw>? MV3lcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? MkS3NlU3Pjd3MUC=
MDA-MB-231 NVjF[VVFTnWwY4Tpc44hSXO|YYm= NEHOZYExNTRyINM1US=> MVS0MVI1KGh? MlzEbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NF\FU4EzPTV6N{OyPS=>
MCF-7 NHS3TJFHfW6ldHnvckBCe3OjeR?= NWq2Zoo2OC12MDFCuW0> NYTWR4pkPC1{NDDo MkXO[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? M4fCfFI2PTh5M{K5
MCF7-MX  NHLFU25HfW6ldHnvckBCe3OjeR?= NFS0RokxNTRyINM1US=> M4\5UFQuOjRiaB?= NUm1b3g6\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?= MnHPNlU2QDd|Mkm=
MDA-MB-231 NHXofGhHfW6ldHnvckBCe3OjeR?= MUKwMVQxKML3TR?= M4q3elQuOjRiaB?= NXr1XHAxe3SrbYXsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCDQlPHNkB2eCC2bzC0MlI4KHSrbXXzJJRwKGOxboTyc4whdGW4ZXygZpkhOTJiaNMg NYnUWnBEOjV3OEezNlk>
A2780 NYL6bGM1TnWwY4Tpc44hSXO|YYm= MkfEOU8yOC9zNTFOwG0> MYm0PEBp NYDaRoJS\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoHzNlU1OjR6OUi=
SKOV3  M{nMfGZ2dmO2aX;uJGF{e2G7 MoTlOU8yOC9zNTFOwG0> NXXEVXB[PDhiaB?= M4jlTIRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1;BV|I2PDJ2OEm4
A2780 NUTHR2FLTnWwY4Tpc44hSXO|YYm= MkTFOU8yOC9zNTFOwG0> MWG0PEBp MnXp[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? MVeyOVQzPDh7OB?=
SKOV3  MoDiSpVv[3Srb36gRZN{[Xl? M2jIT|UwOTBxMUWg{txO M3HnU|Q5KGh? NWHZUY5X\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= M3zGeFI2PDJ2OEm4
A2780 Ml75SpVv[3Srb36gRZN{[Xl? Mo[1OU8yOC9zNTFOwG0> NYDS[mJFPDhiaB?= NHPY[IRl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= MneyNlU1OjR6OUi=
SKOV3  NX[1fGNmTnWwY4Tpc44hSXO|YYm= MX[1M|ExNzF3IN88US=> NVTYbolIPDhiaB?= MkDv[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw NVfLZYF6OjV2MkS4PVg>
A2780 NXL0d2x1TnWwY4Tpc44hSXO|YYm= M3LJdVUwOTBxMUWg{txO MWSxJIg> MXfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXOyOVQzPDh7OB?=
SKOV3  M1nlVWZ2dmO2aX;uJGF{e2G7 MVe1M|ExNzF3IN88US=> MmLpNUBp MkDubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3nVV|I2PDJ2OEm4
HCT-15 NF\ITZBHfW6ldHnvckBCe3OjeR?= MnnuNVAuPTBizszN NYjlTGlWPi1|NjDo Ml;jbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MWGyOVIyQDB{OB?=
HT-29  NIS3WYFHfW6ldHnvckBCe3OjeR?= NWTmdlc3OTBvNUCg{txO MVS2MVM3KGh? M4rEPYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MoTiNlUzOThyMki=
HSC3  NGD4fmVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NELCSXIx6oDVNECg{txO M4P1e|Q5KGh? MYXJR|UxRTJ3LkZCtVEvPzhyIN88US=> NH\0XHczPTF7OEe4PS=>
HSC3  MoPORZBweHSxc3nzJGF{e2G7 M3zJVlI2KM7:TR?= Mn7ZOFghcA>? NY[0NmV7cW6mdXPld{BieG:ydH;zbZM> NUjhcmxbOjVzOUi3PFk>
HSC3  M2fTT2Z2dmO2aX;uJGF{e2G7 MVWyOUDPxE1? MVq0PEBp MYXlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MnfRNlUyQTh5OEm=
HSC3  M3\kPGZ2dmO2aX;uJGF{e2G7 MYKyOUDPxE1? M1j3U|Q5KGh? MljXbY5pcWKrdIOgTHNEOyClZXzsJIlvfmG|aX;uJINwdWKrbnXkJJdqfGhiQ1XU M{DET|I2OTl6N{i5
HSC3  MoPsSpVv[3Srb36gRZN{[Xl? MmrrNlUh|ryP NUi3fJpmPzJiaB?= NY\rXnNT\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh MXeyOVE6QDd6OR?=
201T  NEHib|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3FTXhwPzJiaB?= NYHQR5lFTE2VTx?= M3fUSmlEPTB;NEiuOkDDvU1? MYeyOVA2Pzl2MR?=
273T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rCblczKGh? M{DMdGROW09? NWfjUlVyUUN3ME24NE42KML3TR?= NXrWXIV2OjVyNUe5OFE>
Hep-2 NF21UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWizNE82OC9zMECg{txO MmLTNVIwOjRxM{[vOFghcA>? M33JbmROW09? MlXEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFPqV2EzPDl7OEW2OC=>
Hep-2 M1\DOGFxd3C2b4Ppd{BCe3OjeR?= NHXGT5o2OCEQvF2= M3nXOFAuPDhiaB?= MXLEUXNQ MXTpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NI\udGozPDl7OEW2OC=>
Hep-2 NYfUOFVtTnWwY4Tpc44hSXO|YYm= M3TXbVUxKM7:TR?= MVOwMVQ5KGh? NI\2O|ZFVVOR MkDDdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? MkfiNlQ6QTh3NkS=
Hep-2 MkSxSpVv[3Srb36gRZN{[Xl? MmnuOVAh|ryP MXqwMVQ5KGh? MoP4SG1UVw>? M4rRTYRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV MnHxNlQ6QTh3NkS=
SGC-7901 MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7xNVAwPTBxMUCwJO69VQ>? NEnkW3czPC92OD:3NkBp M372[WROW09? NUCwTlh5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnrHNlQ6QTJ7NUi=
MKN-45 NGXlVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DtdlExNzVyL{GwNEDPxE1? M370TVI1NzR6L{eyJIg> MYLEUXNQ MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYOyOFk6Ojl3OB?=
SGC-7901 NHrZZ|VHfW6ldHnvckBCe3OjeR?= NFPsWHYyOC93MD:xNFAh|ryP M3e2dFQ5KGh? MUnEUXNQ Mn;y[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NX;2cod5OjR7OUK5OVg>
MKN-45 MYfGeY5kfGmxbjDBd5NigQ>? M2rPTlExNzVyL{GwNEDPxE1? MUK0PEBp MXLEUXNQ M1rifIRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUeyOFk6Ojl3OB?=
C666-1 MkPoR5l1d3SxeHnjbZR6KEG|c3H5 NGL3RnIzOC16MDFOwG0> M1rTN|I1KGh? M2LxWoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NV[wZllTOjR6NUS4N|g>
CNE-1 MlW0R5l1d3SxeHnjbZR6KEG|c3H5 NVGwOlI3OjBvOECg{txO MnjtNlQhcA>? NHjFOVNl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MlX5NlQ5PTR6M{i=
CNE-2 M1[1UGN6fG:2b4jpZ4l1gSCDc4PhfS=> MXeyNE05OCEQvF2= M{HPbVI1KGh? Mnza[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> M2DLRlI1QDV2OEO4
C666-1 NYjxfopZS3m2b4TvfIlkcXS7IFHzd4F6 NIPueVc3OCEQvF2= NWDyO2VMPyCm M1u1N4VvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MWqyOFg2PDh|OB?=
CNE-1 MYLDfZRwfG:6aXPpeJkhSXO|YYm= MUK2NEDPxE1? NF70dZE4KGR? MXLlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= NEm0fHYzPDh3NEizPC=>
SNU-1041 M4D0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvOenBROC12MDFOwG0> NVXiVFRqPDhiaB?= NX;hXmx2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MVyyOFY6OjdyMx?=
SNU-1041 NV62c29wTnWwY4Tpc44hSXO|YYm= MWSyNE8{OCEQvF2= M3nQPVQhcA>? NV\HZVR[cW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB? NInrUZQzPDZ7MkewNy=>
SNU-1041 NIPIcppHfW6ldHnvckBCe3OjeR?= MXqwMVQxKM7:TR?= M4\hSlQhcA>? NWqzXpMyfXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= MUSyOFY6OjdyMx?=
SGC-7901 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;LWlUxNTF{NTFOwG0> NGfzUJMzPC92OD:3NkBp MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MX:yOFY4PjN7NB?=
SGC-7901 NH3oR5hCeG:ydH;zbZMhSXO|YYm= NUfWTHNQOTByIN88US=> M3zsXVczKGh? NVjjTHFxcW6mdXPld{BieG:ydH;zbZM> NWDVZ5VPOjR4N{[zPVQ>
SGC-7901 M2iwRmZ2dmO2aX;uJGF{e2G7 M4[3Zlc2NzFyMD:xNlUh|ryP NUW2RpRZOjRxNEivO|IhcA>? NXnzbHN{cW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> M321OFI1Pjd4M{m0
LMeC  NUX1N3B{TnWwY4Tpc44hSXO|YYm= MnmwNlAwPTBizszN Mkm1OFghcA>? NHntZWll\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= M13INlI1PjV4N{S2
CMeC-1 M3zBbmNmdGxiVnnhZoltcXS7IFHzd4F6 NYfMe3J1OjBxNUCg{txO MVS0PEBp MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mo\GNlQ3PTZ5NE[=
LMeC NHPmdHpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWjtelNmOjBxNUCg{txO NGP0SWE1QCCq M2exXIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{fPbFI1PjV4N{S2
CMeC-1 M3vBSmZ2dmO2aX;uJGF{e2G7 MUWyNE82OCEQvF2= MX60PEBp NH3CUXZqdmS3Y3XzJGcyNVNiYYLy[ZN1 MV:yOFY2Pjd2Nh?=
LMeC MX7GeY5kfGmxbjDBd5NigQ>? NH;OdVEzOC93MDFOwG0> MoLLOFghcA>? Mk\ZbY5lfWOnczDHNU1UKGG{cnXzeC=> NHrH[VEzPDZ3Nke0Oi=>
CMeC-1 MU\GeY5kfGmxbjDBd5NigQ>? MknBNlAwPTBizszN M1fMclQ5KGh? NF:3PWll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NX20bVA5OjR4NU[3OFY>
LMeC MmfOSpVv[3Srb36gRZN{[Xl? NU\LTGNlOjBxNUCg{txO M3[2SlQ5KGh? Mlez[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mn7kNlQ3PTZ5NE[=
CMeC-1 MmfwSpVv[3Srb36gRZN{[Xl? M4HqeVIxNzVyIN88US=> MX[0PEBp M4PQcIlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NVHHT|NOOjR4NU[3OFY>
LMeC NHy5[W9HfW6ldHnvckBCe3OjeR?= MlP5NlAwPTBizszN NIPDW3o1QCCq MX7pcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u M2LkUlI1PjV4N{S2
OVCAR-3 NHvBWXhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX3mdWxGOTBiwsXN MXGxJIg> NVrmbYVk\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NYnsXVAyOjR3MkCyNlc>
OVCAR-3 Ml\URZBweHSxc3nzJGF{e2G7 NGX3WXUyOCEEtV2= MomxNUBp NGXqZXVxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? MWSyOFUzODJ{Nx?=
OVCAR-3 MXnGeY5kfGmxbjDBd5NigQ>? NV\5R3JDOTBiwsXN MVmxJIg> Mkfl[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S17wrC= MXuyOFUzODJ{Nx?=
OVCAR-3 M{DsdmZ2dmO2aX;uJGF{e2G7 MVexNEDDvU1? NYqxb4JjOSCq NWX0OHNX\G:5bj3y[Yd2dGG2ZYOgUmYu|rqEIHHjeIl3[XSrb36gbY5lfWOnZDDifUBx[WOuaYThfIVt MUKyOFUzODJ{Nx?=
OVCAR-3 NUfURmZNTnWwY4Tpc44hSXO|YYm= NUj3U5ljOTBiwsXN NX;kSZh{OSCq M{Xw[4lvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v MU[yOFUzODJ{Nx?=
CF33 MYrGeY5kfGmxbjDBd5NigQ>? NF;1TokyODBizszN MYWyOEBp NHT1e3hqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NXu2RW9iOjR3MEO3PFI>
CF33 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;rSHYyOC1zMECg{txO M1PQeFAuPCCm MYfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NV\5O5RvOjR3MEO3PFI>
CF33 M4S1d2Z2dmO2aX;uJGF{e2G7 MoPTNVAuOTByIN88US=> NGq5OG01NTJ2IHi= Mm\h[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 M3[5bVI1PTB|N{iy
LNCaP MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHJNk82NzFyIN88US=> M1HrdFk3KGh? NFT2c5lqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu MWKyOFI6Pjl5OB?=
LNCaP M{PpRWFxd3C2b4Ppd{BCe3OjeR?= NULQNG9tOi93L{GwJO69VQ>? MV:5OkBp NYm4cZMycW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDheI9zfmG|dHH0bY4> M4Xvc|I1Ojl4OUe4
PC-3  NHPHOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOwMVUxKM7:TR?= M1zxR|Q56oDLaB?= MkHpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlHrNlQyOjd6OEK=
PC-3  MnLRR4VtdCCYaXHibYxqfHliQYPzZZk> MnnXNE0yODBizszN MmDEO|IhcA>? MkfD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Ml7ENlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID